Rallybio (RLYB) Other Non-Current Liabilities (2020 - 2021)
Rallybio (RLYB) posted Other Non-Current Liabilities of $32000.0 for Q4 2021, down 8.57% sequentially from $35000.0 in Q3 2021, and up 166.67% YoY from $12000.0 in Q4 2020.
Rallybio (RLYB) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends
Rallybio has reported Other Non-Current Liabilities for 2 years, with the latest figure at $32000.0 in Q4 2021.
- Quarterly Other Non-Current Liabilities rose 166.67% year-over-year to $32000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $32000.0 (up 166.67% YoY) and the FY2021 annual result came in at $32000.0, up 166.67% from the prior year.
- Other Non-Current Liabilities declined to $32000.0 in Q4 2021 per RLYB's latest filing, from $35000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $35000.0 in Q3 2021 and troughed at $12000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 32,000.00 |
| Sep 30, 2021 | 35,000.00 |
| Jun 30, 2021 | 27,000.00 |
| Dec 31, 2020 | 12,000.00 |